4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European stem cell consortium for neural cell replacement, reprogramming and functional brain repair (Neurostemcellrepair)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell ...
Voir le projet
13
Participants partenaires
TERMINÉ
Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet
10
Participants partenaires
TERMINÉ
European Bank for induced pluripotent Stem Cells (EBISC)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,
...e of all stakeholders from tissue donors to clinical and academic iPSC researchers and industrial users, to respond appropriately to advances in science and society. Led by Pfizer Ltd and managed by Roslin Cells, the Consortium comprises 8 active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts in iPSC science, biobankin ...
Voir le projet
30
Participants partenaires
TERMINÉ
Biochemically Equivalent Substitutive Technology for Stem Cells (BEST-Stem cells)
Date du début: 1 juil. 2009, Date de fin: 31 déc. 2012,
Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potentia ...
Voir le projet